Quotient says screening of prototype formulations is crucial to drug delivery

By Natalie Morrison

- Last updated on GMT

Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.

Speaking to Outsourcing-Pharma at this year’s AAPS conference in Washington, the firm’s VP, pharmaceutical sciences Peter Scholes explained the Rapid Fact program – a service Quotient offers to meet drug delivery challenges.

He told us that the main issues clients present are with soluability and half-life of the drug.

“The key challenge is a lack of in vivo,in vitro​ correlation,” said Scholes.

“It’s easy to develop the tablet in the lab to release over six or 12 hours, but the predictability of that in man is very difficult to asses.

“Quotient allow real-time flexibility because of our ability to make and dose on site.”

Related news

Show more

Related products

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers